Nanqu Huang

Dr. Nanqu Huang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Behavioural Brain Research
Verified
Journal Article
Closed access
YZYing Zhang
Ying Zhang
NHNanqu Huang
Nanqu Huang
FYFei Yan
Fei Yan
HJHai Jin
Hai Jin
SZShao-Yu Zhou
Shao-Yu Zhou
FJFeng Jin
Feng Jin

1 January 2017 in Behavioural Brain Research
Verified
Journal Article
Closed access
NHNanqu Huang
Nanqu Huang
HJHai Jin
Hai Jin
SZShao-Yu Zhou
Shao-Yu Zhou
JSjingshan shi
jingshan shi
FJFeng Jin
Feng Jin

8 November 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
WHWendi Huang
Wendi Huang
JHJuan Huang
Juan Huang
NHNanqu Huang
Nanqu Huang
YLYong Luo
Yong Luo
Triggering receptor expressed on myeloid cells 2 (TREM2), a pattern recognition receptor abundantly expressed on microglia, has been identified as one of the risk factors for Alzheimer’s disease (AD). Several studies have already demonstrated the relationship between TREM2 and Tau. TREM2 mutations and altered expression play an important role in Tau phosphorylation. Furthermore, the level of Tau phosphorylation is correlated with soluble TREM2 (sTREM2). However, in different stages of AD, TREM2 seems to have varying effects on Tau pathology. The explicit interaction between TREM2 and Tau, as well as how they affect AD pathology, remains unclear, and there is much evidence to the contrary that requires rational interpretation. Reviewing the dual roles of TREM2 in AD will help identify a more appropriate development strategy for targeting TREM2 to treat AD. Therefore, this review focuses on the interplay between Tau and TREM2 in relation to AD.

19 February 2024 in Cellular and Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
YGYing Ge
Ying Ge
JWJingjing Wu
Jingjing Wu
LZLi Zhang
Li Zhang
NHNanqu Huang
Nanqu Huang
YLYong Luo
Yong Luo
Neuroinflammation is an important pathogenesis of neurological diseases and causes a series of physiopathological changes, such as abnormal activation of glial cells, neuronal degeneration and death, and disruption of the blood‒brain barrier. Therefore, modulating inflammation may be an important therapeutic tool for treating neurological diseases. Mesenchymal stem cells (MSCs), as pluripotent stem cells, have great therapeutic potential for neurological diseases due to their regenerative ability, immunity, and ability to regulate inflammation. However, recent studies have shown that MSC-derived exosomes (MSC-Exos) play a major role in this process and play a key role in neuroprotection by regulating neuroglia. This review summarizes the recent progress made in regulating neuroinflammation by focusing on the mechanisms by which MSC-Exos are involved in the regulation of glial cells through signaling pathways such as the TLR, NF-κB, MAPK, STAT, and NLRP3 pathways to provide some references for subsequent research and therapy. Graphical Abstract Exosomes derived from MSCs exhibit neuroprotective effects by regulating signaling pathways and mitigating neuroinflammation triggered by glial cells.

28 March 2024 in Heliyon
Verified
Journal Article
Open access
JYJuan Yu
Juan Yu
ZZZhanghong Zhao
Zhanghong Zhao
YLYuanyuan Li
Yuanyuan Li
JCJian Chen
Jian Chen
NHNanqu Huang
Nanqu Huang
YLYong Luo
Yong Luo
Parkinson's disease (PD) is a neurodegenerative disorder with motor symptoms like bradykinesia, tremors, and balance issues. The pathology is recognized by progressively degenerative nigrostriatal dopaminergic neurons (DANs) loss. Its exact pathogenesis is unclear. Numerous studies have shown that nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) contributes to the pathogenesis of PD. Previous studies have demonstrated that the over-activation of NLRP3 inflammasome in microglia indirectly leads to the loss of DANs, which can worsen PD. In recent years, autopsy analyses of PD patients and studies in PD models have revealed upregulation of NLRP3 expression within DANs and demonstrated that activation of NLRP3 inflammasome in neurons is sufficient to drive neuronal loss, whereas microglial activation occurs after neuronal death, and that inhibition of intraneuronal NLRP3 inflammasome prevents degeneration of DANs. In this review, we provide research evidence related to NLRP3 inflammasome in DANs in PD as well as focus on possible mechanisms of NLRP3 inflammasome activation in neurons, aiming to provide a new way of thinking about the pathogenesis and prevention of PD.

2 August 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
YLYunzhen Lei
Yunzhen Lei
MXMin Xu
Min Xu
NHNanqu Huang
Nanqu Huang
ZYZhengqiang Yuan
Zhengqiang Yuan
Objective: The objective of this study was to study the effect of probiotics or synbiotics on the risk factors for coronary artery disease (CAD) in the context of conventional drug therapy for CAD.Methods: The literature on probiotics or synbiotics for the treatment of CAD was collected from PubMed, Scopus, Web of Science, Embase, and Cochrane Library. The search period was conducted on November 5, 2022, and the search covered all literature before November 5, 2022. The included literature consisted of randomized controlled trials of probiotics or synbiotics for CAD, and a meta-analysis was performed using Stata 14 software and RevMan 5.4 software.Results: The meta-analysis explored the effect of probiotics or synbiotics on the risk factors for coronary artery lesions in a treatment setting with conventional medications for CAD. After a rigorous literature screening process, 10 studies were finally included for data consolidation to objectively evaluate the effect of probiotics or synbiotics on coronary lesions. The results of this study showed that the addition of probiotics or synbiotics to conventional medications for CAD reduced the levels of low-density lipoprotein cholesterol [weighted mean difference (WMD) −9.13 (−13.17, −5.09)], fasting glucose (FPG) [WMD −13.60 (−23.57, −3.62)], and hypersensitive C-reactive protein (hs-CRP) [standardized mean difference (SMD) −0.60 (−0.83, −0.37)] and increased the levels of high-density lipoprotein cholesterol (HDL-C) [WMD 1.94 (0.32, 3.57)], nitric oxide (NO) [WMD 5.38 (3.23, 7.54)] but did not affect the triglyceride (TG) level [WMD −13.41 (−28.03, 1.21)], systolic blood pressure (SBP) [WMD −0.88 (−3.72, 1.96)], or diastolic blood pressure (DBP) [WMD −0.21 (−2.19, 1.76)].Conclusion: Adding probiotics or synbiotics to conventional medications for CAD may improve patient prognosis.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022362711.